Skip to main content

Advertisement

SpringerLink
Log in

Radiologically isolated syndromes: to treat or not to treat?

  • Review
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

The widespread use of magnetic resonance imaging (MRI) has led to increased detection of individuals exhibiting asymptomatic brain and spinal cord lesions suggestive of multiple sclerosis (MS), defined as “radiologically isolated syndrome” (RIS). Specific criteria have been proposed and updated over time to identify individuals with RIS. Moreover, a younger age, the presence of infratentorial, spinal cord or gadolinium-enhancing lesions, as well as of cerebrospinal fluid-specific oligoclonal bands have been recognized as relevant risk factors for the occurrence of a first clinical event. Recent randomized controlled trials conducted in individuals with RIS have shown that dimethyl fumarate and teriflunomide significantly reduce the occurrence of clinical events in this population. These findings support the notion that early treatment initiation may positively influence the prognosis of these patients. However, several aspects should be taken into account before treating individuals with RIS in the real-world clinical setting, including an accurate identification of individuals with RIS to avoid misdiagnosis, a precise stratification of their risk of experiencing a first clinical event and further data supporting favorable balance between benefits and risks, even in the long term. This commentary provides an overview of the latest updates in RIS diagnosis, prognosis, and emerging treatment evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Not applicable.

References

  1. Sunny DE, Amoo M, Al Breiki M, Teng EDW, Henry J, Javadpour M (2022) Prevalence of incidental intracranial findings on magnetic resonance imaging: a systematic review and meta-analysis. Acta Neurochir (Wien) 164(10):2751–2765. https://doi.org/10.1007/s00701-022-05225-7

    Article  PubMed  Google Scholar 

  2. Morris Z, Whiteley WN, Longstreth WT Jr, Weber F, Lee YC, Tsushima Y et al (2009) Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 339:b3016. https://doi.org/10.1136/bmj.b3016

    Article  PubMed  PubMed Central  Google Scholar 

  3. De Stefano N, Giorgio A, Tintore M, Pia Amato M, Kappos L, Palace J et al (2018) Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. Mult Scler 24(2):214–221. https://doi.org/10.1177/1352458517717808

    Article  PubMed  Google Scholar 

  4. Lebrun-Frenay C, Kantarci O, Siva A, Azevedo CJ, Makhani N, Pelletier D et al (2023) Radiologically isolated syndrome. Lancet Neurol 22(11):1075–1086. https://doi.org/10.1016/S1474-4422(23)00281-8

    Article  PubMed  Google Scholar 

  5. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS et al (2009) Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 72(9):800–805. https://doi.org/10.1212/01.wnl.0000335764.14513.1a

    Article  CAS  PubMed  Google Scholar 

  6. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173. https://doi.org/10.1016/S1474-4422(17)30470-2

    Article  PubMed  Google Scholar 

  7. Engell T (1989) A clinical patho-anatomical study of clinically silent multiple sclerosis. Acta Neurol Scand 79(5):428–430. https://doi.org/10.1111/j.1600-0404.1989.tb03811.x

    Article  CAS  PubMed  Google Scholar 

  8. Gilbert JJ, Sadler M (1983) Unsuspected multiple sclerosis. Arch Neurol 40(9):533–536. https://doi.org/10.1001/archneur.1983.04050080033003

    Article  CAS  PubMed  Google Scholar 

  9. Phadke JG, Best PV (1983) Atypical and clinically silent multiple sclerosis: a report of 12 cases discovered unexpectedly at necropsy. J Neurol Neurosurg Psychiatry 46(5):414–420. https://doi.org/10.1136/jnnp.46.5.414

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yamout B, Al KM (2017) Radiologically isolated syndrome and multiple sclerosis. Mult Scler Relat Disord 17:234–237. https://doi.org/10.1016/j.msard.2017.08.016

    Article  CAS  PubMed  Google Scholar 

  11. Forslin Y, Granberg T, Jumah AA, Shams S, Aspelin P, Kristoffersen-Wiberg M et al (2016) Incidence of radiologically isolated syndrome: a population-based study. AJNR Am J Neuroradiol 37(6):1017–1022. https://doi.org/10.3174/ajnr.A4660

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH et al (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120(Pt 11):2059–2069. https://doi.org/10.1093/brain/120.11.2059

    Article  PubMed  Google Scholar 

  13. Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C et al (2021) 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 20(8):653–670. https://doi.org/10.1016/S1474-4422(21)00095-8

    Article  PubMed  Google Scholar 

  14. Lebrun-Frenay C, Okuda DT, Siva A, Landes-Chateau C, Azevedo CJ, Mondot L et al (2023) The radiologically isolated syndrome: revised diagnostic criteria. Brain 146(8):3431–3443. https://doi.org/10.1093/brain/awad073

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lebrun-Frenay C, Kantarci O, Siva A, Sormani MP, Pelletier D, Okuda DT et al (2020) Radiologically isolated syndrome: 10-year risk estimate of a clinical event. Ann Neurol 88(2):407–417. https://doi.org/10.1002/ana.25799

    Article  CAS  PubMed  Google Scholar 

  16. Lebrun-Frenay C, Rollot F, Mondot L, Zephir H, Louapre C, Le Page E et al (2021) Risk factors and time to clinical symptoms of multiple sclerosis among patients with radiologically isolated syndrome. JAMA Netw Open 4(10):e2128271. https://doi.org/10.1001/jamanetworkopen.2021.28271

    Article  PubMed  PubMed Central  Google Scholar 

  17. Matute-Blanch C, Villar LM, Alvarez-Cermeno JC, Rejdak K, Evdoshenko E, Makshakov G et al (2018) Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain 141(4):1085–1093. https://doi.org/10.1093/brain/awy021

    Article  PubMed  Google Scholar 

  18. Okuda DT, Mowry EM, Cree BA, Crabtree EC, Goodin DS, Waubant E et al (2011) Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 76(8):686–692. https://doi.org/10.1212/WNL.0b013e31820d8b1d

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M et al (2014) Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS ONE 9(3):e90509. https://doi.org/10.1371/journal.pone.0090509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kantarci OH, Lebrun C, Siva A, Keegan MB, Azevedo CJ, Inglese M et al (2016) Primary progressive multiple sclerosis evolving from radiologically isolated syndrome. Ann Neurol 79(2):288–294. https://doi.org/10.1002/ana.24564

    Article  PubMed  Google Scholar 

  21. Lebrun-Frenay C, Siva A, Sormani MP, Landes-Chateau C, Mondot L, Bovis F et al (2023) Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical trial. JAMA Neurol 80(10):1080–1088. https://doi.org/10.1001/jamaneurol.2023.2815

    Article  PubMed  Google Scholar 

  22. Okuda DT, Kantarci O, Lebrun-Frenay C, Sormani MP, Azevedo CJ, Bovis F et al (2023) Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. Ann Neurol 93(3):604–614. https://doi.org/10.1002/ana.26555

    Article  CAS  PubMed  Google Scholar 

  23. Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M et al (2022) Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol 269(10):5382–5394. https://doi.org/10.1007/s00415-022-11193-w

    Article  PubMed  PubMed Central  Google Scholar 

  24. Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH et al (2022) The CELLO trial: protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Mult Scler Relat Disord 68:104143. https://doi.org/10.1016/j.msard.2022.104143

    Article  PubMed  PubMed Central  Google Scholar 

  25. Baker D, Pryce G, James LK, Marta M, Schmierer K (2020) The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Mult Scler Relat Disord 44:102279. https://doi.org/10.1016/j.msard.2020.102279

    Article  PubMed  Google Scholar 

  26. George IC, Rice DR, Chibnik LB, Mateen FJ (2021) Radiologically isolated syndrome: a single-center, retrospective cohort study. Mult Scler Relat Disord 55:103183. https://doi.org/10.1016/j.msard.2021.103183

    Article  CAS  PubMed  Google Scholar 

  27. Suthiphosuwan S, Sati P, Guenette M, Montalban X, Reich DS, Bharatha A et al (2019) The central vein sign in radiologically isolated syndrome. AJNR Am J Neuroradiol 40(5):776–783. https://doi.org/10.3174/ajnr.A6045

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Oh J, Suthiphosuwan S, Sati P, Absinta M, Dewey B, Guenette M et al (2021) Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS. Mult Scler 27(14):2199–2208. https://doi.org/10.1177/13524585211002097

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Landes-Chateau C, Levraut M, Okuda DT, Themelin A, Cohen M, Kantarci OH et al (2024) The diagnostic value of the central vein sign in radiologically isolated syndrome. Ann Clin Transl Neurol. https://doi.org/10.1002/acn3.51986

    Article  PubMed  PubMed Central  Google Scholar 

  30. Giorgio A, Stromillo ML, Rossi F, Battaglini M, Hakiki B, Portaccio E et al (2011) Cortical lesions in radiologically isolated syndrome. Neurology 77(21):1896–1899. https://doi.org/10.1212/WNL.0b013e318238ee9b

    Article  CAS  PubMed  Google Scholar 

  31. Suthiphosuwan S, Sati P, Absinta M, Guenette M, Reich DS, Bharatha A et al (2020) Paramagnetic rim sign in radiologically isolated syndrome. JAMA Neurol 77(5):653–655. https://doi.org/10.1001/jamaneurol.2020.0124

    Article  PubMed  PubMed Central  Google Scholar 

  32. Bonzano L, Bove M, Sormani MP, Stromillo ML, Giorgio A, Amato MP et al (2019) Subclinical motor impairment assessed with an engineered glove correlates with magnetic resonance imaging tissue damage in radiologically isolated syndrome. Eur J Neurol 26(1):162–167. https://doi.org/10.1111/ene.13789

    Article  CAS  PubMed  Google Scholar 

  33. Amato MP, Hakiki B, Goretti B, Rossi F, Stromillo ML, Giorgio A et al (2012) Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology 78(5):309–314. https://doi.org/10.1212/WNL.0b013e31824528c9

    Article  CAS  PubMed  Google Scholar 

  34. Filippi M, Preziosa P, Barkhof F, Chard DT, De Stefano N, Fox RJ et al (2021) Diagnosis of progressive multiple sclerosis from the imaging perspective: a review. JAMA Neurol 78(3):351–364. https://doi.org/10.1001/jamaneurol.2020.4689

    Article  PubMed  Google Scholar 

  35. Rotstein D, Montalban X (2019) Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 15(5):287–300. https://doi.org/10.1038/s41582-019-0170-8

    Article  PubMed  Google Scholar 

  36. Lassmann H (2018) Multiple sclerosis pathology. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a028936

    Article  PubMed  PubMed Central  Google Scholar 

  37. Correale J, Gaitan MI, Ysrraelit MC, Fiol MP (2017) Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain 140(3):527–546. https://doi.org/10.1093/brain/aww258

    Article  PubMed  Google Scholar 

  38. Filippi M, Preziosa P, Langdon D, Lassmann H, Paul F, Rovira A et al (2020) Identifying progression in multiple sclerosis: new perspectives. Ann Neurol 88(3):438–452. https://doi.org/10.1002/ana.25808

    Article  PubMed  Google Scholar 

  39. Krieger SC, Cook K, De Nino S, Fletcher M (2016) The topographical model of multiple sclerosis: a dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflamm 3(5):e279. https://doi.org/10.1212/NXI.0000000000000279

    Article  PubMed  PubMed Central  Google Scholar 

  40. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374(9700):1503–1511. https://doi.org/10.1016/S0140-6736(09)61259-9

    Article  CAS  PubMed  Google Scholar 

  41. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP et al (2014) Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13(10):977–986. https://doi.org/10.1016/S1474-4422(14)70191-7

    Article  CAS  PubMed  Google Scholar 

  42. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67(7):1242–1249. https://doi.org/10.1212/01.wnl.0000237641.33768.8d

    Article  CAS  PubMed  Google Scholar 

  43. Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N et al (2019) Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain 142(7):1858–1875. https://doi.org/10.1093/brain/awz144

    Article  PubMed  PubMed Central  Google Scholar 

  44. Solomon AJ (2019) Diagnosis, differential diagnosis, and misdiagnosis of multiple sclerosis. Continuum (Minneap Minn) 25(3):611–635. https://doi.org/10.1212/CON.0000000000000728

    Article  PubMed  Google Scholar 

  45. Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L et al (2023) Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. Lancet Neurol 22(8):750–768. https://doi.org/10.1016/S1474-4422(23)00148-5

    Article  PubMed  Google Scholar 

  46. Rival M, Thouvenot E, Du Trieu de Terdonck L, Laurent-Chabalier S, Demattei C, Uygunoglu U et al (2023) Neurofilament light chain levels are predictive of clinical conversion in radiologically isolated syndrome. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/NXI.0000000000200044

    Article  PubMed  Google Scholar 

  47. Lebrun C, Bensa C, Debouverie M, Wiertlevski S, Brassat D, de Seze J et al (2009) Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol 66(7):841–846. https://doi.org/10.1001/archneurol.2009.119

    Article  PubMed  Google Scholar 

Download references

Funding

No targeted funding reported.

Author information

Authors and Affiliations

  1. Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy

    Paolo Preziosa, Maria A. Rocca & Massimo Filippi

  2. Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Paolo Preziosa, Maria A. Rocca & Massimo Filippi

  3. Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Massimo Filippi

  4. Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy

    Massimo Filippi

  5. Vita-Salute San Raffaele University, Milan, Italy

    Paolo Preziosa, Maria A. Rocca & Massimo Filippi

Authors
  1. Paolo Preziosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria A. Rocca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Massimo Filippi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Filippi.

Ethics declarations

Conflict of interest

Paolo Preziosa received speaker honoraria from Roche, Biogen, Novartis, Merck Serono, Bristol Myers Squibb and Genzyme; he has received research support from Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. Maria A. Rocca received consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche; and speaker honoraria from AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for Multiple Sclerosis and Related Disorders. Massimo Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.

Ethical standards

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Preziosa, P., Rocca, M.A. & Filippi, M. Radiologically isolated syndromes: to treat or not to treat?. J Neurol 271, 2370–2378 (2024). https://doi.org/10.1007/s00415-024-12294-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-024-12294-4

Keywords

Search

Navigation